Abstract -Asthma is related to various cardiovascular risk. Whether a history of asthma from childhood contributes to arterial stiffness in adulthood, a noninvasive surrogate for cardiovascular events, is unknown. Prospective analyses were performed among 1746 Bogalusa Heart Study participants aged 20 to 51 years with data on self-report asthma collected since childhood. Aorta-femoral pulse wave velocity (af-PWV, m/s) was repeatedly assessed among adults ≥aged 18 years. Generalized linear mixed models and generalized linear models were fitted for the repeated measurements of af-PWV and its changes between the last and the first measurements, respectively. After a median follow-up of 11.1 years, participants with a history of asthma from childhood had a higher af-PWV (6.78 versus 6.13; P=0.048) and a greater increase in af-PWV (8.99 versus 2.95; P=0.043) than those without asthma, adjusted for age, sex, race, smoking status, heart rate, body mass index, systolic blood pressure, lipids, and glycemia. In addition, we found significant interactions of asthma with body mass index and systolic blood pressure on af-PWV and its changes (P for interaction <0.01). The associations of asthma with af-PWV and its changes appeared to be stronger among participants who were overweight and obese (body mass index ≥25 kg/m 2 ) or with prehypertension and hypertension (systolic blood pressure ≥120 mm Hg) compared with those with a normal body mass index or systolic blood pressure. Our findings indicate that a history of asthma from childhood is associated with higher af-PWV and greater increases in af-PWV, and such associations are stronger among young adults who are overweight or with elevated blood pressure. (Hypertension. 2018;71:928-936.
A rterial stiffness expressed as pulse wave velocity (PWV) is a functional marker of arterial vulnerability and recognized as organ damage, resulting from aging, arteriosclerosis, and elevated blood pressure. [1] [2] [3] [4] In hypertensive patients or those with established diseases (eg, type 2 diabetes mellitus, heart disease, chronic kidney, and pulmonary diseases), persistent elevation of aortic PWV is related to high risk for future death and adverse cardiovascular events. [5] [6] [7] Growing evidence has shown that accelerated stiffening of central elastic arteries, especially in children and young adults, is a strong independent predictor for cardiovascular events, cardiac disease, renal disease, and future death. 2, [8] [9] [10] [11] Recently, a growing body of evidence has linked increased PWV with chronic inflammation, [12] [13] [14] [15] independent of traditional cardiovascular risk factors.
Asthma is a chronic inflammatory disorder characterized by inflamed and narrowed airways, affecting 8.4% (6.2 million) of children and 7.6% (18.4 million) of adults in the United States in 2015. 16 Adult patients with asthma have been found to have an increased risk of incident stroke and total cardiovascular events. 17, 18 However, there are limited data linking asthma with subclinical vessel changes and cardiac dysfunction, and the findings are inconsistent. [19] [20] [21] Several cross-sectional studies of both pediatric and adult populations have found a positive association between asthma and PWV. 19, [21] [22] [23] To our knowledge, there have been no prospective studies assessing the relationship between a history of asthma from childhood and aortic PWV and its changes in young adults.
In this study, we evaluated the association between a history of asthma from childhood and aorta-femoral PWV (af-PWV) in young adulthood using data from the BHS (Bogalusa Heart Study), an ongoing, community-based, epidemiological study begun in 1973. 24 In addition, we particularly investigated potential interactions between asthma and major cardiovascular risk factors.
Methods

Study Participants and Data Source
The BHS is a community-based, biracial (65% white and 35% black), series of surveys to determine the natural history of cardiovascular disease and its risk factors, established by Dr Gerald S. Berenson in 1973. 24 A total of ≈16 000 individuals have been recruited in BHS surveys, including 9 surveys of children and adolescents aged 4 to 19 years from 1973 till 1994 and 11 surveys of adults aged 20 to 52 years who were examined during childhood and remained accessible from 1977 till now. 25 It now consists of series of surveys and is ongoing still, with examinations every 2 to 3 years from childhood through adulthood. Thus, the repeated measurements of both cardiovascular function and cardiovascular disease risk factors enabled longitudinal analyses in a unique childhood-to-adulthood cohort setting. A detailed description of study design and participant recruitment in BHS was provided elsewhere. 26 Data, analytic methods, and study materials are available to other researchers through National Heart, Lung, and Blood Institute BioLINCC repository at https://biolincc. nhlbi.nih.gov/studies/bhs/ or through ClinicalTrials.gov at https:// clinicaltrials.gov/ct2/show/NCT00005129.
In the current study, baseline information on a history of asthma since childhood was collected among 8289 individuals using a selfadministered questionnaire from September 27, 1983 , to December 29, 2010. Noninvasive cardiac subclinical markers derived from echocardiography were measured as the outcomes in the followups from February 14, 2001 , to December 29, 2010 . We excluded subjects who only had baseline information on asthma, or who did not have subclinical cardiac measurements in the follow-ups, or whose self-reported asthma was reported after cardiac markers were measured. In addition, we excluded subjects who had a physiciandiagnosed or self-reported cardiovascular disease from baseline to follow-up, including arteritis, angina pectoris, angioplasty, blockage in ventricle, bypass surgery, congenital heart disease, congestive cardiac failure, enlarged left ventricle, heart murmur, heart attack, mitral valve prolapse, mitral valve stenosis, stroke, tachyarrhythmia, ventricular arrhythmia, valve replacement, and unspecified mitral disease. 27 After applying the exclusion criteria, a total of 1746 participants formed the study cohort ( Figure 1) , with 1 to 4 follow-ups apiece. To examine the impact of asthma on longitudinal changes in af-PWV, a minimum of 5 years' time interval between the first and last echocardiographs was required for included participants (434 subjects included). Written informed consent was obtained from adult participants and from parent/guardian of children and adolescent at each examination circle. The study protocol was approved by the biomedical committee of the Tulane University Institutional Review Board.
History of Asthma
Individual information on a history of asthma was collected by questionnaire. Asthma prevalence was measured by the child's parent/guardian's responding to the question does your child now have asthma or has your child had asthma in the past?. The survey time was approximately considered as the age of asthma diagnosis for children and teenagers. Adults aged >18 years of old were asked the following question: do you now have asthma or have you had asthma in the past?. For participants who reported having asthma in the past, they were further asked the following question: when were you first diagnosed with asthma?. If this information was missing, the survey time then became the proxy time of diagnosis. For those with multiple times of reported asthma, the first report of asthma was considered as the baseline for asthmatic subjects, and the time when firstly reporting of no asthma was used for those who never reported asthma from 1983 to 2010.
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Assessment of af-PWV
af-PWVs were measured using the Toshiba Power Vision SSH-380 (Toshiba America Medical Systems, Tustin, CA), with 1 nondirectional transcutaneous Doppler flow probe (Toshiba PSK25AT, 2.5 MHz) positioned at the suprasternal notch and another probe (Toshiba PCK703AT, 7.5 MHz) at left femoral artery in a supine position. 28 The arterial flow waves from the 2 arterial sites were recorded. The distance between the aorta and femoral arteries was measured with a caliper instrument. 29 The difference in timing between the 2 waves represents the time component of the velocity equation. Then Figure 1 . Flowchart of the study sample. #CVD from baseline to followup, including arteritis, angina pectoris, angioplasty, blockage in ventricle, bypass surgery, congenital heart disease, congestive cardiac failure, enlarged left ventricle, heart murmur, heart attack, mitral valve prolapse, mitral valve stenosis, stroke, tachyarrhythmia, ventricular arrhythmia, valve replacement, and unspecified mitral disease. af-PWV indicates aorta-femoral pulse wave velocity; and CVD, cardiovascular disease.
af-PWV was calculated by dividing the distance traveled by the time differential between 2 waveforms, and the mean value of af-PWV from 3 repeated measurements was used for each participant. 30 In addition, a random 6% sample of participants were selected for repeat measurements 10 to 12 days apart. As described elsewhere, 30 ,31 the coefficient of variation for inter-reader and intrareader variability for all measures of cardiac anatomy was <10%. The echocardiography was performed among adults aged ≥18 years, with height ranged from 133 to 196 cm.
Assessment of Covariates
Demographic information were all self-reported or reported by parents or guardians on self-administrated questionnaires, including age in years at screening, sex (male/female), race (white/black), smoking status (current/noncurrent smokers), use of antihypertensive medicine (yes/no), medication for dyslipidemia (yes/no), and medication for glycemia (yes/no). Physical and laboratory examinations followed rigid protocols performed by trained examiners. Body mass index (BMI, weight in kilograms divided by the square of the height in meters) was repeatedly measured, and the mean values were used for analysis. Resting heart rate (beats per minute) was counted at the radial pulse in a relaxed sitting position, and 3 measurements were obtained separated by brief intervals. Systolic and diastolic blood pressures (the fourth Korotkoff phase for children and the fifth for adults) were measured using a mercury sphygmomanometer by 2 well-trained observers (3 replicates each). The cutoff value of 120 mm Hg for systolic blood pressure (SBP), according to the update in the 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, 32 was used to define prehypertension and hypertension in the current study. The mean value of the 6 readings of blood pressure was used for analysis. Fasting overnight was required for laboratory examination. Total cholesterol and low-density lipoprotein cholesterol levels (mg/ dL) were determined by enzymatic procedures on the Abbott VP instrument (Abbott Laboratories, Chicago, IL) from 1987 to 1996 and on the Hitachi 902 Automatic Analyzer (Roche Diagnostics, Indianapolis, IN) after 1996. Fasting plasma glucose (mg/dL) was measured by a glucose oxidase method using a Beckman Glucose Analyzer (Beckman Instruments, Palo Alto, CA) from 1981 to 1991 and measured enzymatically as part of a multichemistry (SMA20) profile since 1991. 33 Information on covariates was obtained during the same day when the echocardiography was completed in the examining center.
Statistical Analyses
Characteristics of the subjects were compared between asthma and nonasthma groups using the χ 2 test for categorical variables and the Student t test or Kruskal-Wallis test for continuous variables with normal or skewed distributions, respectively. We fitted a generalized linear mixed model to examine the association of asthma with repeated af-PWV measures. Statistical adjustments were made for age, sex, race, smoking status, use of antihypertensive medicine, medication for dyslipidemia, medication for glycemia, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, and heart rate as fixed effects, as well as individual ID as random effects. Furthermore, we estimated the least-squares means and confidence intervals of af-PWV with adjustment for covariates. To examine the potential interactions, we categorized age (<35 and ≥35 years), heart rate (<70 and ≥70 beats per minutes), SBP (<120 and ≥120 mm Hg), total cholesterol (<200 and ≥200 mg/dL), low-density lipoprotein cholesterol (<130 and ≥130 mg/dL), fasting glucose (<100 and ≥100 mg/dL) into 2 groups, and BMI (<25, 25-30, and ≥30 kg/m 2 ) into 3 groups (Table 3 ) and then included the interaction term of asthma and each covariate (considered as both categorical and continuous variables) in the generalized linear mixed model. Similarly, we fitted a generalized linear model to assess the association between asthma and the changes in af-PWV (△af-PWV) with additional adjustments of the first af-PWV measurement and the time interval between the first and last af-PWV measurements. A 2-sided P<0.05 was considered as statistically significant, and false discovery rate from P values was computed for multiple testing corrections using the Benjamine and Hochberg. All data management and analyses were conducted using R version 3.3.0 released on May 3, 2016. Table 1 summarizes the characteristics of the study subjects at both baseline and follow-up by asthma status. With ‡In the follow-ups, 764 participants were with just 1-time follow-up measurement, and the rest of 982 participants were with 2 to 4 repeated followup af-PWV measurements, which added up to a total of 3180 observations. The follow-up years were calculated starting from the baseline questionnaire until the last af-PWV measurement.
Results
a median follow-up of 11.1 years, 1746 participants were included, with a total of 3944 follow-up measurements of af-PWV, and 56.2% of them were followed 2× to 4×. Of the longitudinal cohort (58.2% were women, and 28.9% were blacks), 9.7% had a self-reported history of asthma. The median (interquartile range) of age was 29.0 years (15.0, 34.0 years) and 37.0 years (29.0, 43.0 years) of old at baseline and in the last follow-up, respectively. Compared with participants without asthma, subjects who had a history of asthma were younger at both baseline (22.5 versus 29.5; P<0.01) and last follow-up (36.0 versus 37.0; P=0.02) and had a higher BMI (30.8 versus 29.3; P=0.02). No significant difference was found in sex, race, smoking, SBP, heart rate, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, and medication for hypertension, dyslipidemia, and diabetes mellitus.
In Table 2 , participants with a history of asthma since childhood had significantly higher af-PWV in their young adulthood compared with those without asthma after full adjustment (6.78 versus 6.13; P=0.048). We also examined the association of asthma with the changes in af-PWV (△af-PWV, m/s), measured during a median of 11.1 years (interquartile range: 5.4-13.0 years) among 434 subjects. Of note, participants with a history of asthma had almost a 3-fold greater increase in af-PWV compared with those without asthma (adjusted means of △af-PWV: 9.52 versus 3.60; P=0.032). Further adjustment for SBP or BMI did not appreciably change the associations (P<0.05).
We further analyzed the potential interactions between a history of asthma and major cardiovascular risk factors on af-PWV and its changes, using the Benjamini and Hochberg false discovery rate procedure for multiple testing correction (Table 3) . We found that both BMI and SBP significantly modified the association of asthma with af-PWV and △af-PWV (P false discovery rate for interaction <0.05). For young adults who were overweight or obese (BMI ≥25 kg/m 2 ), significant differences in af-PWV and △af-PWV were both observed between asthma and nonasthma group (adjusted means: 7.19 versus 6.27 for af-PWV in Figure 2A ; 12.73 versus 1.83 for △af-PWV in Figure 2B ,; P values for both regression coefficients [β] <0.01). For participants who were with prehypertension or hypertension (SBP ≥120 mm Hg), similar differences were also shown between 2 groups (β=2.26 for af-PWV in Figure 2C , P<0.01; β=13.12 for △af-PWV in Figure 2D , P=0.01), whereas among subjects with normal weight (BMI <25 kg/m 2 ) or SBP <120 mm Hg, the difference in af-PWV and △af-PWV between asthma and nonasthma groups was not significant (β=−0.236 and −4.289, P=0.792 and 0.531, respectively, for af-PWV in Figure 2A and △af-PWV in Figure 2B ; β=−0.246 and 0.735, P=0.545 and 0.834, respectively, for af-PWV in Figure 2C and △af-PWV in Figure 2D ). No significant interactions were observed between asthma and other risk factors.
Discussion
In this longitudinal cohort of a median follow-up of 11 year, a history of asthma from childhood was significantly associated with a greater af-PWV and accelerated the increase in △af-PWV among asymptomatic young adults, independent of traditional cardiovascular risk factors. We observed significant interactions of asthma with SBP and BMI on af-PWV and △af-PWV; the positive associations of asthma with af-PWV af-PWV indicates aorta-femoral pulse wave velocity; △af-PWV, longitudinal changes in aorta-femoral pulse wave velocity; BMI, body mass index; CI, confidence interval; and SBP, systolic blood pressure.
*Model 1 used a generalized linear mixed model (GLMM) in participants with asthma (n=169) or without asthma (n=1577), controlled for age (y), sex (male/female), race (black/white), smoking status (current smokers/noncurrent smokers), use of antihypertensive medicine (yes/no), medication for dyslipidemia (yes/no), medication for glycemia (yes/no), total cholesterol (mg/ dL), low-density lipoprotein cholesterol (mg/dL), fasting glucose (mg/dL), and heart rate (beats per min) as fixed effects, as well as individual ID as random effects.
†The time interval between the first and last PWV measurements was ranged from 5.0 to 16.1 y (median=11.5). Model 1 used a generalized linear model (GLM) in participants with asthma (n=32) or without asthma (n=402), controlled for age (y), interval time between the first and the last af-PWV measurements (y), sex (male/female), race (black/white), smoking status (current smokers/noncurrent smokers), use of antihypertensive medicine (yes/no), total cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), fasting glucose (mg/dL), heart rate (beats per min), and PWV at baseline (m/s). af-PWV indicates aorta-femoral pulse wave velocity; △af-PWV, longitudinal changes in aorta-femoral pulse wave velocity; BMI, body mass index; CI, confidence interval; FDR, false discovery rate; LDL-C, low-density lipoprotein cholesterol; and SBP, systolic blood pressure.
*Stratified analysis was performed according to different groups of each covariate. Generalized linear mixed models (GLMM) were used to adjust for age (y), sex (male/female), race (black/white), smoking status (current smokers/noncurrent smokers), use of antihypertensive medicine (yes/no), medication for dyslipidemia (yes/ no), medication for glycemia (yes/no), total cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), fasting glucose (mg/dL), and heart rate (beats per min) as fixed effects, as well as individual ID as random effects. The interaction term of asthma and according to covariate was included in the GLMMs.
†Stratified analysis was performed according to different groups of each covariate. Generalized linear models (GLM) were used to adjust for age (y), follow-up period (y), sex (male/female), race (black/white), smoking status (current smokers/noncurrent smokers), use of antihypertensive medicine (yes/no), total cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), fasting glucose (mg/dL), heart rate (beats per min), and PWV at baseline (m/s). The interaction term of asthma and according to covariate was included in the GLMs.
‡P values with FDR correction of the interaction term in each GLMM/GLM models were given, considering both asthma and the covariates as binary variables. §P values with FDR correction of the interaction term in each GLMM/GLM models were given, considering both asthma and the covariates as continuous variables.
and its change appeared to be stronger among participants with higher BMI (overweight and obese) or higher SBP (prehypertension and hypertension) compared with those who had a lower BMI and SBP. To our knowledge, the current study is the first to prospectively analyze the association between a history of asthma from childhood and arterial stiffness in young adults. Results from a meta-analysis of 17 prospective cohort studies showed that 1.0 m/s increase in aortic PWV was associated with 14%, 15%, and 15% increase in total cardiovascular events, cardiovascular mortality, and all-cause mortality, respectively.
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Of note, our study participants are young adults, and a small increase in af-PWV is a reliable marker for an abnormally accelerated stiffing in central arteries in the early adulthood. 34 In addition, previous studies have indicated that significant clinical difference in cardiovascular risks in middle age might originate from a small difference of PWV in early adulthood. 11, 35 Our results were in line with several previous cross-sectional studies performed in middle-aged adults, in which asthma and its severity were related to a higher risk of elevated arterial stiffness. 21, 23 However, such associations were inconsistent in children and adolescents. 19, 22 Our findings showing asthma associated with PWV indicate that a history of asthma from childhood may contribute to the acceleration of central arterial stiffness and subsequently increased cardiovascular risk. Although our previous findings have suggested an adverse impact of asthma on left ventricular mass, 27 a structural measure of myocardial vulnerability, the current study provides incremental evidence of its detrimental impact on impaired vessel function.
In the current study, a history asthma from childhood is independently associated with higher af-PWV and a greater increase in △af-PWV. However, the potential mechanisms underlying these associations remain unclear. Given the fact that asthmatic patients were accompanied by elevated levels of inflammatory biomarkers, [36] [37] [38] as well as increased arterial stiffness in chronic inflammatory disorders, 13, 14 the shared pathogenesis of systemic inflammation could play an important role in linking asthma and arterial stiffness. Pulmonary function decline in asthmatics might also partly account for this association. Wu et al 39 demonstrated higher brachial-ankle PWV with restrictive spirometry patterns, a 116% and 95% increase in the risk of arterial stiffness in men and women, respectively. In addition, medicine for asthma (including oral corticosteroids, short-acting β agonists, and their combinations) has been reported to increase the risk of incident Figure 2 . Interaction of asthma with body mass index (BMI) and systolic blood pressure (SBP) on aorta-femoral pulse wave velocity (af-PWV) and its longitudinal changes. Adjusted means and 95% confident intervals of the repeated measurements of af-PWV were calculated using generalized linear mixed models (GLMM) stratified by BMI (A) and SBP (C), controlled for age, sex, race, smoking status, use of antihypertensive medicine, medication for dyslipidemia, medication for glycemia, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, and heart rate as fixed effects, as well as individual ID as random effects. Adjusted means and 95% confident intervals of the 11-y changes in af-PWV (△af-PWV) were calculated using generalized linear models (GLM) stratified by BMI (B) and SBP (D), controlled for age, sex, race, smoking status, use of antihypertensive medicine, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, and heart rate. β was the regression coefficient of asthma on af-PWV (left) and its changes (right) in stratified BMI and SBP groups in GLMMs or GLMs, followed by its P values for statistical significance. P values with false discovery rate correction for interaction term were given by including the interaction term in the GLMMs or GLMs. cardiovascular events and death. 40, 41 Moreover, patients with asthma demonstrate a more sedentary lifestyle, [42] [43] [44] and such unhealthy lifestyle may also adversely affect aortic stiffness. 31, 45, 46 Intriguingly, we found the significant interactions of asthma with BMI and SBP on af-PWV and △af-PWV-the associations of a history of asthma from childhood on central arterial stiffness and its progress in a later life were stronger among young adults who were overweight and obese or who had prehypertension or hypertension. Supportively, 2 longitudinal population-based studies showed similar interactions between asthma and hypertension on coronary vasospastic angina and peripheral artery disease (P for interaction=0.062 and 0.142, respectively). 47, 48 Despite the lack of direct evidence, such interactions were biologically possible. Considered the most common comorbidities in the asthmatics, [49] [50] [51] [52] both obesity 53 and high blood pressure 54, 55 may worsen the existing risk profiles, including systematic inflammation, 5, 50, 56, 57 leptin and adiponectin regulation, [58] [59] [60] and vascular trophic factors, 61, 62 which leads to acceleration of arterial stiffness during the aging process.
In the current study, the community-based prospective cohort provided us a unique opportunity to examine the association of a history of asthma from childhood with arterial stiffness among asymptomatic young adults. Repeated echocardiographic measurements during a long follow-up period enabled us to evaluate the impact of asthma on the progress of aortic stiffness over time. The availability of covariate information enabled us to control for potential confounders and performing interaction analyses. In addition, correction for multiple testing was adopted in our interaction analyses to reduce type Ⅰ error. However, several limitations should be considered. First, data on asthma were self-reported from questionnaires, rather than physician diagnosed or through clinical records. Second, the relatively small sample size yielded wide 95% confidence intervals in subgroups. Third, although a variety of covariates was carefully controlled for in our analyses, residual confounders remained (eg, childhood af-PWV at baseline, the severity of asthma and its medication, pulmonary function, physical activity, excessive alcohol consumption, and diet). Forth, it would be better to include systemic inflammatory biomarkers at baseline in our major analyses to elucidate the presumed mechanism between systematic inflammation/ oxidative stress at baseline and increased arterial stiffness in follow-ups.
Perspectives
Our results for the first time provided evidence that a history of asthma from childhood was significantly associated with higher af-PWV and a greater increase in af-PWV over time in young adults, independent of traditional cardiovascular risk factors. In addition, such associations were more prominent among participants who are overweight or with elevated SBP. Our data underscore the importance for the prevention and control of asthma in pediatric and young adult population and the need for lifestyle interventions among asthmatic patients, especially those with a high BMI or elevated SBP, to mitigate cardiovascular complications.
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